Investor Relations
Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.
Redemption Date Announced for Warrants
Apr 15, 2024
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants. Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas , April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Mar 25, 2024
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at